|
07:35 AM EST, 01/22/2021 (MT Newswires) -- Theralase Technologies (TLT.V) a clinical stage pharmaceutical company researching light activated Photo Dynamic Compounds (PDC) to destroy various cancers, bacteria and viruses, on Friday announced that it has expanded its Intellectual Property (IP) portfolio. Theralase has been notified by its legal council that there have been three recent decisions to grant a patent in Russia, India and China. The Russian and Indian patent protect the company's systemic and targeted anti-cancer therapies to allow PDCs and their associated drug formulations to be systemically injected to hunt and locate into cancer cells for various cancer conditions. Once located in the cancer cells of interest they can be activated by laser light or radiation to destroy the cancer cells safely and effectively. The Chinese patent opens up new oncological applications, including targeting cancers that are difficult, if not impossible to reach with surgery, such as GlioBlastoma Multiforme (GBM), a deadly form of brain cancer, Non-Small Cell Lung Cancer (NSCLC) or other deep tissue related cancers. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase(r) stated that, "These patents are strategic to opening up new international opportunities for Theralase and its expanding platform of medical laser and oncology related technologies. They validate the proprietary IP position of the company's anti-cancer technology for the Russian, Indian and Chinese healthcare markets, demonstrating Theralase's ongoing commitment to the development of a comprehensive IP portfolio. Our long-term strategy is to commercialize the anti-cancer technology that commenced with NMIBC and then expand into GBM, NSCLC, and other various cancer indications to provide a safe and effective alternative treatment option for patients inflicted with these deadly diseases. The ability to provide personalized treatment for cancer patients to hunt and destroy their cancer and prevent its recurrence, all in a single or dual treatment, remains at the forefront of our minds". |